InvestorsTransforming Drug & Cell Delivery
At Likarda, we’re unlocking the full potential of biologics and cell therapies through our patented Core-Shell Spherification® (CSS) platform. Designed for precision, durability, and immune protection, our technology enables targeted, long-acting delivery across some of the most complex therapeutic areas, from fragile peptides to allogeneic cells.
Why Invest in Likarda?
$250B+ Market Opportunity
We sit at the convergence of biologics, regenerative medicine, and cell therapy—sectors expected to surpass $250B globally within five years. Yet delivery remains the bottleneck. Likarda solves this with a differentiated, platform-first approach.
Versatile Platform with High Licensing Potential
CSS® is a modular, tunable encapsulation system compatible with a wide range of therapies—from injectable peptides to live cell constructs. Each application represents a distinct opportunity for co-development, licensing, or out-licensing.
Accelerated Regulatory Pathway
Our platform leverages GRAS-listed, highly biocompatible materials within a closed-loop, GMP-ready process, dramatically simplifying regulatory navigation and speeding time to clinic.
Revenue-Generating Partnerships
We are actively engaged in paid feasibility studies with top-tier biopharma and biotech companies—proof of strong demand, validation of our platform’s utility, and traction for long-term partnerships.
Scalable Equipment Launch in 2026
In 2026, we will launch our automated CSS® encapsulation system, enabling plug-and-play adoption across clinical and commercial settings. This expansion opens recurring revenue streams through instrument sales, services, and consumables.
Let’s Build the Future of Therapeutic Delivery—Together
Likarda is actively raising capital to fuel our next phase of growth, accelerating equipment deployment, expanding our commercial pipeline, and scaling operations. Partner with us to define the future of targeted, regenerative delivery.